Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01430
|
|||||
| Drug Name |
Pirarubicin
|
|||||
| Synonyms |
pirarubicin; Theprubicin; MFCD00869742; THP-doxorubicin; C32H37NO12; NCGC00167982-01; AC1LCS5T; Pirarubicin (JP17/INN); SCHEMBL15472856; CHEMBL1398373; EX-A494; AOB5649; KMSKQZKKOZQFFG-HSUXVGOQSA-N; ZINC3913909; AKOS015895621; NCGC00167982-02; BC225325; K234; D01885; 15207-EP2316833A1; 15207-EP2311829A1; 15207-EP2298765A1; 15207-EP2298748A2; 15207-EP2295427A1; 15207-EP2295416A2; 15207-EP2272827A1; 15207-EP2316832A1; 15207-EP2298778A1; 15207-EP2298768A1; 15207-EP2295426A1; 15207-EP2295055A2; 15207-EP2311808A1
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H37NO12
|
|||||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6
|
|||||
| InChI |
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1
|
|||||
| InChIKey |
KMSKQZKKOZQFFG-HSUXVGOQSA-N
|
|||||
| Pharmaceutical Properties | Molecular Weight | 627.6 | Topological Polar Surface Area | 204 | ||
| Heavy Atom Count | 45 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 13 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:32011
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (D58G680W0G) | |||||
| 2 | Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.